Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP422619.RAhfNCi67fdQM4tYJ09htFs-LYrhl5zSU6eWisQxgdIKg130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP422619.RAhfNCi67fdQM4tYJ09htFs-LYrhl5zSU6eWisQxgdIKg130_provenance.
• NP679216.RA5LTZObZW42byZX9V8sDNB4YNCw8UUoE2CpOxsGnr8Bw130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679216.RA5LTZObZW42byZX9V8sDNB4YNCw8UUoE2CpOxsGnr8Bw130_provenance.
• assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP861509.RADvNUsMCRhyIwqiS7s91V72YrD-PrPS18TFVXNGT4w88130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861509.RADvNUsMCRhyIwqiS7s91V72YrD-PrPS18TFVXNGT4w88130_provenance.
• NP493413.RAbmbVsqvOiSQr3v_tPqXYCXn84js0f2eGetFMccM95pg130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493413.RAbmbVsqvOiSQr3v_tPqXYCXn84js0f2eGetFMccM95pg130_provenance.
• NP493414.RASxpEMr2Aai6PkzrLS1qTxPs0gdGfifJ5EF-5va8J-_A130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493414.RASxpEMr2Aai6PkzrLS1qTxPs0gdGfifJ5EF-5va8J-_A130_provenance.
• NP493410.RAoUl3rAvBP54Hj5TayctI0eAlR7j-opXmRDCJwh-5j0Q130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493410.RAoUl3rAvBP54Hj5TayctI0eAlR7j-opXmRDCJwh-5j0Q130_provenance.
• NP493408.RAKbx2Yc_xNMtkuYWPXOdEiLJiMw3L-9DOb8bKMa106vo130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493408.RAKbx2Yc_xNMtkuYWPXOdEiLJiMw3L-9DOb8bKMa106vo130_provenance.
• NP861463.RAwH2QGk1TidWk9-aIlsrU7rIdQ8cuOv4QFjZJgil-b2I130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861463.RAwH2QGk1TidWk9-aIlsrU7rIdQ8cuOv4QFjZJgil-b2I130_provenance.
• NP493412.RA9WZgx2-tW8IA_GWL8xJEcTdMXIcHw2N6W8aQ3YUk9Mw130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493412.RA9WZgx2-tW8IA_GWL8xJEcTdMXIcHw2N6W8aQ3YUk9Mw130_provenance.
• NP493416.RA8ZmKTW0x5Ux8p0gRz1tcdCEazycLiQx16KG5Yf-6hCo130_assertion description "[LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493416.RA8ZmKTW0x5Ux8p0gRz1tcdCEazycLiQx16KG5Yf-6hCo130_provenance.